Interleukin (IL-)1 is an important mediator of inflammatory responses and plays an important role in the pathogenesis of various @entity792 . @entity13592 ( @entity13592 ) is a multisystem @entity792 . We have studied the role of @entity1192 in its pathogenesis. We have investigated the serum levels of @entity1192 components ( @entity1192 , @entity1356 , and @entity1193 ), and determined the role of intravenous immunoglobulin (IVIg) therapy in @entity1 with @entity13592 . Serum levels of @entity1192 and beta were significantly higher in untreated @entity1 with active disease compared to levels in @entity1 in prolonged clinical remission and normal @entity1 controls (P<0.0001). The serum levels of @entity1193 were higher in @entity1 in prolonged clinical remission compared to @entity1 with active disease (P=0.002). Hence elevated levels of @entity1192 and beta and low levels of @entity1193 correlate with disease activity. The levels of @entity1192 and beta were statistically significantly higher in sera of @entity13592 @entity1 with active disease pre-IVIg therapy compared to post-IVIg therapy (P<0.0001). Statistically significantly higher levels of @entity1193 were present in post-IVIg treatment serum samples when compared to levels in pre-IVIg treatment (P<0.0001). In the in vitro experiments, the levels of @entity1192 and beta produced by the peripheral blood mononuclear cells (PBMC) isolated from @entity1 before IVIg therapy were significantly higher when compared to the PBMC isolated from post-IVIg @entity1 (P<0.0001). Significantly higher levels of @entity1193 were observed in the supernatants of PBMC collected from pre-IVIg @entity1 and cultured with exogenously added IVIg, when compared to the levels of PBMC to which IVIg was not added (P<0.0001). @entity1192 may be an important cytokine involved in the pathogenesis of @entity13592 . The regulation of @entity1192 could be one of the mechanisms, amongst others, by which IVIg may exert its beneficial effect in the treatment of @entity13592 .

XXXX components in cicatricial pemphigoid. Role in intravenous immunoglobulin therapy.

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity1356 :: ('3553', 'Gene') :: ['IL-1beta'] @entity1193 :: ('3557', 'Gene') :: ['IL-1Ra'] @entity1192 :: ('3552', 'Gene') :: ['IL-1', 'IL-1alpha'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune inflammatory disease', 'autoimmune diseases'] @entity13592 :: ('MESH:D010390', 'Disease') :: ['Cicatricial pemphigoid', 'CP']
@entity1192 :: (3552,Gene) :: ['Interleukin 1']
